317 related articles for article (PubMed ID: 25344374)
1. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Hartung HP; Aktas O; Boyko AN
Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
[TBL] [Abstract][Full Text] [Related]
3. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis.
Fadul CE; Mao-Draayer Y; Ryan KA; Noelle RJ; Wishart HA; Channon JY; Kasper IR; Oliver B; Mielcarz DW; Kasper LH
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34654708
[TBL] [Abstract][Full Text] [Related]
4. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Barclay K; Carruthers R; Traboulsee A; Bass AD; LaGanke C; Bertolotto A; Boster A; Celius EG; de Seze J; Cruz DD; Habek M; Lee JM; Limmroth V; Meuth SG; Oreja-Guevara C; Pagnotta P; Vos C; Ziemssen T; Baker DP; Wijmeersch BV
Front Neurol; 2019; 10():253. PubMed ID: 30967831
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.
Caon C; Meyer C; Mayer L; Smith MS
Int J MS Care; 2013; 15(4):159-68. PubMed ID: 24453779
[TBL] [Abstract][Full Text] [Related]
6. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.
Baker D; Ali L; Saxena G; Pryce G; Jones M; Schmierer K; Giovannoni G; Gnanapavan S; Munger KC; Samkoff L; Goodman A; Kang AS
Front Immunol; 2020; 11():124. PubMed ID: 32117274
[TBL] [Abstract][Full Text] [Related]
7. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
Coles AJ; Achiron A; Traboulsee A; Singer BA; Pozzilli C; Oreja-Guevara C; Giovannoni G; Comi G; Freedman MS; Ziemssen T; Shiota D; Rawlings AM; Wong AT; Chirieac M; Montalban X
Ther Adv Neurol Disord; 2023; 16():17562864231194823. PubMed ID: 37745914
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
Kang C; Blair HA
Drugs; 2022 Jan; 82(1):55-62. PubMed ID: 34897575
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Coles AJ; Arnold DL; Bass AD; Boster AL; Compston DAS; Fernández Ó; Havrdová EK; Nakamura K; Traboulsee A; Ziemssen T; Jacobs A; Margolin DH; Huang X; Daizadeh N; Chirieac MC; Selmaj KW
Ther Adv Neurol Disord; 2021; 14():1756286420982134. PubMed ID: 34035833
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers.
Diem L; Ovchinnikov A; Friedli C; Hammer H; Kamber N; Chan A; Salmen A; Findling O; Hoepner R
Mult Scler Relat Disord; 2024 Jun; 86():105570. PubMed ID: 38604001
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
Okai AF; Amezcua L; Berkovich RR; Chinea AR; Edwards KR; Steingo B; Walker A; Jacobs AK; Daizadeh N; Williams MJ;
Neurol Ther; 2019 Dec; 8(2):367-381. PubMed ID: 31654272
[TBL] [Abstract][Full Text] [Related]
13. Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
Emma C; Vesela P; Kay P; Huseyin H; Alison H; Mara S; Floriana A; Sara C
Mult Scler; 2024 Jun; 30(7):893-897. PubMed ID: 38385208
[TBL] [Abstract][Full Text] [Related]
14. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Rolla S; Maglione A; De Mercanti SF; Clerico M
Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
[TBL] [Abstract][Full Text] [Related]
15. Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety.
Zeydan B
Eur J Paediatr Neurol; 2023 Mar; 43():A1. PubMed ID: 36990951
[No Abstract] [Full Text] [Related]
16. Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.
Hecker M; Fitzner B; Boxberger N; Putscher E; Engelmann R; Bergmann W; Müller M; Ludwig-Portugall I; Schwartz M; Meister S; Dudesek A; Winkelmann A; Koczan D; Zettl UK
J Neuroinflammation; 2023 Aug; 20(1):181. PubMed ID: 37533036
[TBL] [Abstract][Full Text] [Related]
17. Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis.
Nosher S; Fuad S; Mishra N; Alrashid ZA; Rathod B; Mohan D; Basavanagowda DM; Kaur A; Heindl SE
Cureus; 2021 Feb; 13(2):e13246. PubMed ID: 33728194
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune storm following alemtuzumab.
Chan C; Beauchemin P; Sayao AL; Carruthers M
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
[TBL] [Abstract][Full Text] [Related]
19. The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective.
Alroughani R; Van Wijmeersch B; Al Khaboori J; Alsharoqi IA; Ahmed SF; Hassan A; Inshasi J; Krieger DW; Shakra M; Shatila AO; Szolics M; Khallaf M; Ezzat A
Ther Adv Neurol Disord; 2020; 13():1756286420954119. PubMed ID: 32973927
[TBL] [Abstract][Full Text] [Related]
20. Glomerulonephritis after Alemtuzumab Treatment for Multiple Sclerosis: A Report of Two Cases.
Almuhaiteeb A; Alkeay K; Altaleb A
Glomerular Dis; 2024; 4(1):84-90. PubMed ID: 38660579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
